SR&ED Tax Credits and the Exfiltration of Canadian Intellectual Property

Overview

This applied topic connects corporate control and intellectual-property arrangements with research tax incentives. It asks a policy question: how far does subsidizing research performed in Canada secure the later economic benefits of that research? “Exfiltration” describes the concern about value moving abroad; it does not establish that a particular transfer is unlawful.

Keep three inquiries separate: eligibility for Scientific Research and Experimental Development (SR&ED), the claimant's status and credit calculation, and the tax consequences of cross-border transactions. A valid research project does not establish CCPC status, and a foreign licence does not by itself establish tax abuse.

The corporate-law lessons draw their framework from the supplied JurisClasseur. This extension uses the Income Tax Act (ITA) and the official federal and Quebec materials linked below for tax rules and current program changes. It is an introduction to the interaction of those regimes, not a complete tax-computation course. Review shareholders' agreements before applying the control discussion.

Learning Objectives

• Separate eligible work, expenditures, status, rate and refundability, and explain why Canadian voting ownership alone does not establish CCPC status.
• Test a numerical policy claim by distinguishing assumed subsidies, revenue, taxable profit and a supported counterfactual.
• Distinguish enacted SR&ED changes from policy proposals and separate transfer pricing, GAAR and substantive-CCPC rules.

The Architecture of Canada's SR&ED Tax Incentive

Statutory Foundations Under the Income Tax Act

Section 37 concerns the deduction of eligible research expenditures; sections 127 and 127.1 govern the investment tax credit and refundability. These are related calculations, not identical pools. Government assistance, contract payments and other adjustments can change the qualified expenditure base.

The definition in subsection 248(1) concerns systematic scientific or technological investigation by experiment or analysis. The work must seek scientific or technological advancement; commercial success is not required. Routine quality control, market research and ordinary commercial production are excluded, while qualifying support work must be connected and commensurate with the eligible research. Calling a project innovative or employing scientists does not settle eligibility. CRA: eligible work.

Distinguish current expenditures, qualifying capital expenditures and the overhead method. Subsection 127(10.2) calculates the CCPC expenditure limit; it is not the provision establishing the proxy method. A deduction against income and a refundable credit have different effects on a company with no tax payable.

The CCPC Advantage and the Two-Tier Rate Structure

The basic Investment Tax Credit rate is 15%. Eligible CCPCs and, under the new regime, eligible Canadian public corporations may earn 35% within their expenditure limit. Refundability is a separate question: the CRA's current table distinguishes corporation categories, current expenditures and capital expenditures. Many eligible corporations receive a full refund of the enhanced credit on current expenditures, while enhanced credits on qualifying capital expenditures are generally only 40% refundable. Excluded-corporation rules also matter.

Unused non-refundable credits can generally be carried back three tax years or forward twenty; current profitability is therefore not their only possible source of value. CRA: current rates and refundability.

The Provincial Layer and the Quebec Context

Federal and provincial percentages cannot simply be added. The bases, exclusions, assistance adjustments and overhead methods must be identified first. A provincial credit can reduce the federal qualified expenditure base; a single asserted percentage of wages does not explain the combined calculation.

For Quebec, distinguish the legacy R&D measures from the CRIC for taxation years beginning after March 25, 2025. The new regime's exclusion threshold means that “30% on the first million” is incomplete without identifying the expenditures above that threshold. The provincial rules are discussed below; a federal eligibility conclusion does not automatically establish every provincial condition.

The Economics of Intellectual Property Exfiltration

The Innovation Paradox and the Jenkins Report

The 2011 Jenkins panel recommended simplifying SR&ED for smaller firms, redirecting part of the support toward complementary direct measures and using procurement to encourage innovation. That is historical policy advice, not a judicial finding that particular foreign-controlled companies were legally entitled to enhanced credits. Jenkins executive summary, recommendations 2–3.

The policy question remains analytically useful: research employment, knowledge spillovers, ownership of IP and later taxable income are different outcomes. A subsidy can support domestic research even where foreign parties obtain exploitation rights. Whether that is good policy requires evidence about benefits and alternatives; whether it is lawful requires the relevant statutory analysis.

Corporate Structuring and the Manipulation of De Jure Control

De jure control concerns legal voting power, interpreted with the corporation's governing documents and any relevant unanimous shareholder agreement. It is only part of the CCPC inquiry. Subsection 125(7) excludes specified foreign or public-company control, includes an aggregation rule, and must be read with subsections 256(5.1) and (5.11). Control in fact considers all relevant influence, not only an enforceable power to replace the board. ITA, s. 125(7), s. 256(5.1)–(5.11).

A Canadian-Controlled Private Corporation cannot be established merely by assigning voting shares to Canadian nominees while a foreign investor exercises control in fact. Conversely, a large non-voting economic interest is evidence to examine, not an automatic substitute for the statutory tests. Review voting agreements, appointment rights, financing dependence, vetoes and actual influence, including the limited arm's-length commercial-agreement exception in subsection 256(5.1).

Cost-Sharing Agreements and Transfer Pricing Mechanisms

A Cost-sharing agreement allocates contributions, risks and expected benefits among participants. Its label does not determine the tax result. Transfer pricing under section 247 tests the arrangement against the Arm's length principle, including the parties' actual conduct, functions, assets and risks. A paper allocation of worldwide rights is not conclusive evidence of their appropriate value.

The current section 247, amended in 2026, expressly addresses economically relevant characteristics and arm's-length conditions. Contributions must be evaluated against reasonably expected benefits; an assumed Canadian percentage of the world market cannot mechanically determine the proper allocation for a particular technology. Payments received for research also require examination in calculating the Canadian claim. ITA, s. 247.

A Numerical Case Study in Value Stripping

Factual Scenario

Hypothetical with stipulated figures, not a reported tax case. A Canadian research company has $12 million of qualifying wage costs over four years. For this exercise only, assume its status and all credit calculations have been verified and that its total net public assistance is $5.04 million. A foreign participant receives non-Canadian exploitation rights under an agreement whose arm's-length terms have not yet been tested.

Later licensing produces $80 million of revenue and $50 million of deductible costs, leaving $30 million of taxable profit under the simplifying assumptions. Use assumed effective tax rates of 12.5% abroad and 26.5% in Canada, with no other taxes, credits or differences. Does this prove a $21.2 million Canadian tax loss or establish abusive avoidance?

Variation

Before any claim is filed, evidence shows that the foreign investor controls the private corporation in fact, despite Canadians holding the voting common shares. Can the assumed enhanced CCPC credit still be used?

Legislative and Doctrinal Countermeasures

The Limits of Section 247 and Traditional GAAR

Transfer pricing and the General Anti-Avoidance Rule answer different questions. Section 247 examines non-arm's-length cross-border conditions; section 245 addresses a tax benefit from an avoidance transaction involving misuse or abuse. Valuation uncertainty does not exempt an early-stage IP transaction from either regime.

Nor does later commercial success automatically prove an earlier price was wrong: the relevant evidence includes the arrangement and reasonable expectations at the time, assessed under the applicable rules. Reassessment periods and their extensions require separate analysis. It is unsafe to assume that the ordinary period invariably protects an arrangement by the time valuable technology emerges.

The Substantive CCPC Rules and Modernized Economic Substance

Substantive CCPC is a distinct category concerning private corporations that are not CCPCs but meet the specified Canadian-resident-individual control or aggregated-share tests. The rules principally address investment-income tax deferral; they do not deem every foreign-controlled research subsidiary eligible for enhanced SR&ED assistance. Finance explanatory notes, CRA investment-income treatment.

Under current GAAR, obtaining a tax benefit as one of the main purposes engages the avoidance-transaction inquiry. A significant lack of economic substance is an important consideration tending toward misuse or abuse, not an automatic presumption deciding the case. The 25% penalty has statutory calculation rules and disclosure and reliance exceptions; it is not mandatory in every cross-border restructuring. ITA, s. 245(3)–(5.2).

The 2024 to 2026 Modernization Wave

The Doubling of the Expenditure Limit to Six Million Dollars

Bill C-15 received Royal Assent on March 26, 2026. The annual maximum expenditure limit increased from $3 million to $6 million for taxation years beginning after December 15, 2024, and the CCPC taxable-capital phase-out range increased to $15–75 million. These are enacted changes, not merely the earlier budget proposals. CRA legislative update.

At the full limit, 35% of $6 million is $2.1 million. That arithmetic is not an unconditional refund per enterprise: the qualified base, group allocation, applicable limit and refundability still matter. Prior-year taxable income ceased to reduce the CCPC expenditure limit for years ending after March 18, 2019; distinguish that change from separate refundability conditions.

Extension to Canadian Public Corporations

The definition of eligible Canadian public corporation in subsection 127(9) includes Canadian residence, the specified public-corporation condition, foreign-control restrictions and an aggregated non-resident-share test, as well as an eligible-subsidiary route. It is not confined to an actual listing on a Canadian exchange. The expenditure-limit rules for this category use revenue, including the relevant consolidated-group calculation, rather than simply transplanting the CCPC capital test. ITA, s. 127(9), (10.6)–(10.64).

Qualifying capital expenditures made after December 15, 2024 are again eligible. Acquisition, use and available-for-use conditions must be checked; not every laboratory purchase qualifies, and credit eligibility does not imply full refundability. CRA capital-expenditure policy.

The Federal Patent Box Debate and Consultation Outcomes

A patent box concerns preferential taxation of qualifying IP income, whereas SR&ED subsidizes eligible research expenditure. The distinction matters for a company with no current taxable profit: reducing an income-tax rate and refunding a research credit supply different support.

Canada consulted on a patent-box regime in 2024, and the 2024 Fall Economic Statement announced an intention to implement one. Those historical announcements must not be treated as enacted eligibility rules or as proof of a later formal rejection. Compare policy proposals with the actual amending legislation before calculating any tax benefit. 2024 consultations, 2024 Fall Economic Statement.

Quebec's Transition to the CRIC and CDAEIA

The Credit for Research, Innovation, and Commercialization (CRIC), described by Revenu Québec in English as the tax credit for R&D, innovation and pre-commercialization, applies to qualifying years beginning after March 25, 2025. It provides 20%, increased to 30% on up to $1 million of qualifying expenditures above the exclusion threshold. That threshold is the greater of $50,000 and the relevant employee-threshold total. Pre-commercialization and certain capital expenditures have their own conditions; purchasing IP is not automatically eligible. Revenu Québec: CRIC.

CDAEIA concerns specified AI-related e-business activities for years beginning after December 31, 2025. Its scope includes qualifying preparatory work and specialized AI consulting, subject to conditions and exclusions; it is not simply an “AI software coding only” rule. Annual company and employee attestations, revenue tests and employment conditions must be considered. Investissement Québec: CDAEIA.

Strategic Implications for Practitioners and Tech Enterprises

Corporate Structuring and IP Ownership Safeguards

For an applied corporate-law problem, map the ownership of shares separately from ownership of inventions, code and exploitation rights. Identify assignments, licences, employee and contractor arrangements, and governance approvals. Canadian retention can be a business or policy objective without being a universal statutory condition for every research credit.

The useful planning question is whether the chosen rights, financing and allocation of risks reflect the actual arrangement and satisfy each applicable regime. Neither a nominal Canadian board nor a blanket prohibition on foreign licensing substitutes for that analysis.

Managing CRA Audits and Technological Documentation

Keep evidence of technological uncertainty, the systematic investigation, work performed and expenditures claimed. Failed experiments can contribute to scientific or technological knowledge; ordinary business uncertainty is insufficient. Scientific eligibility and financial substantiation remain separate inquiries.

The CRA launched optional pre-claim approval on April 1, 2026. That service does not turn every later expenditure into an approved credit. Documentation, corporate status and the actual claim must still be assessed. The legal questions about scientific eligibility differ from timesheets and accounting substantiation; neither form of record alone proves that the work meets the scientific definition. CRA eligibility guidance, program update.

Practice Checklist

• Fix the taxation year and distinguish announcement, enactment and effective date.
• Identify eligible work, qualified expenditure adjustments and the appropriate credit calculation separately.
• Check legal and factual control, applicable aggregation rules and any public-corporation route.
• Distinguish the maximum expenditure limit from the corporation's allocated limit and refundable amount.
• Separate IP ownership, transfer pricing, investment-income rules and GAAR.
• For a policy calculation, label assumptions and distinguish revenue, taxable profit, tax difference and a supported fiscal counterfactual.
• Apply Quebec's thresholds and attestations independently; federal eligibility is not a complete provincial analysis.